keyword
MENU ▼
Read by QxMD icon Read
search

Pca3

keyword
https://www.readbyqxmd.com/read/28524004/urinary-biomarkers-for-prostate-cancer
#1
Francesca Giunchi, Chiara Ciccarese, Rodolfo Montironi, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Holger Moch, Francesco Massari, Michelangelo Fiorentino
Urine may represent a convenient source of biomarkers for the early detection of prostate cancer (PCa) since contains secreted prostatic products and exfoliated tumor cells. Furthermore urine are easy to collect with non-invasive procedures and they are repeatable. Several urinary biomarkers for PCa have been proposed in the past but only one (PCA3) has been approved for clinical use and even this is not widely utilized in the routine practice. Most of these, particularly the proteins, were abandoned due to lack of confirmation...
May 18, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/28520829/association-between-combined-tmprss2-erg-and-pca3-rna-urinary-testing-and-detection-of-aggressive-prostate-cancer
#2
Martin G Sanda, Ziding Feng, David H Howard, Scott A Tomlins, Lori J Sokoll, Daniel W Chan, Meredith M Regan, Jack Groskopf, Jonathan Chipman, Dattatraya H Patil, Simpa S Salami, Douglas S Scherr, Jacob Kagan, Sudhir Srivastava, Ian M Thompson, Javed Siddiqui, Jing Fan, Aron Y Joon, Leonidas E Bantis, Mark A Rubin, Arul M Chinnayian, John T Wei, Mohamed Bidair, Adam Kibel, Daniel W Lin, Yair Lotan, Alan Partin, Samir Taneja
Importance: Potential survival benefits from treating aggressive (Gleason score, ≥7) early-stage prostate cancer are undermined by harms from unnecessary prostate biopsy and overdiagnosis of indolent disease. Objective: To evaluate the a priori primary hypothesis that combined measurement of PCA3 and TMPRSS2:ERG (T2:ERG) RNA in the urine after digital rectal examination would improve specificity over measurement of prostate-specific antigen alone for detecting cancer with Gleason score of 7 or higher...
May 18, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28489592/diagnostic-significance-of-urinary-long-non-coding-pca3-rna-in-prostate-cancer
#3
Tao Wang, Xiangyun Qu, Jiajia Jiang, Peng Gao, Dingding Zhao, Xueqi Lian, Xiaohua Li
Prostate cancer antigen 3(PCA3) is a long non-coding RNA, which was found increased expression in CaP patients than healthy individual. In this study, the individual nucleic acid of PCA3 and PSA was recombinant expressed as a reference reagent, and a quantitative RT-PCR with TaqMan assay was developed to examine the copies of PCA3 and PSA gene in urine. The results showed that the area under the receiver operating characteristic curve (AUROC) was 0.717, 0.444 and 0.916 for the number of PCA3 copy, PSA copy and for the score of PCA3/PSA RNA, respectively...
April 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28485411/prostate-cancer-pca3-as-a-grade-reclassification-predictor
#4
Annette Fenner
No abstract text is available yet for this article.
May 9, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28441042/aberrantly-expressed-long-noncoding-rnas-in-recurrent-implantation-failure-a-microarray-related-study
#5
Li-Juan Fan, Hong-Jing Han, Jing Guan, Xiao-Wei Zhang, Qing-Hua Cui, Huan Shen, Cheng Shi
Long noncoding RNAs (lncRNAs) are a class of noncoding RNAs longer than 200 nucleotides. They were long regarded as transcription noise for their low expression and non-protein coding features. Recent published reports indicate that lncRNAs are involved in virtually every aspect of human biology. We aimed to profile the endometrial lncRNA expression pattern in women with recurrent implantation failure (RIF) and predict the function of the genes of the dysregulated lncRNA transcripts. Endometrial samples (24) were collected during window of implantation (14 RIF women and 10 women who conceived after embryo transfer)...
April 25, 2017: Systems Biology in Reproductive Medicine
https://www.readbyqxmd.com/read/28419548/detection-of-prostate-cancer-specific-transcripts-in-extracellular-vesicles-isolated-from-post-dre-urine
#6
Kathryn L Pellegrini, Dattatraya Patil, Kristen J S Douglas, Grace Lee, Kathryn Wehrmeyer, Mersiha Torlak, Jeremy Clark, Colin S Cooper, Carlos S Moreno, Martin G Sanda
BACKGROUND: The measurement of gene expression in post-digital rectal examination (DRE) urine specimens provides a non-invasive method to determine a patient's risk of prostate cancer. Many currently available assays use whole urine or cell pellets for the analysis of prostate cancer-associated genes, although the use of extracellular vesicles (EVs) has also recently been of interest. We investigated the expression of prostate-, kidney-, and bladder-specific transcripts and known prostate cancer biomarkers in urine EVs...
June 2017: Prostate
https://www.readbyqxmd.com/read/28417979/longitudinal-assessment-of-urinary-pca3-for-predicting-prostate-cancer-grade-reclassification-in-favorable-risk-men-during-active-surveillance
#7
J J Tosoian, H D Patel, M Mamawala, P Landis, S Wolf, D J Elliott, J I Epstein, H B Carter, A E Ross, L J Sokoll, C P Pavlovich
BACKGROUND: To assess the utility of urinary prostate cancer antigen 3 (PCA3) as both a one-time and longitudinal measure in men on active surveillance (AS). METHODS: The Johns Hopkins AS program monitors men with favorable-risk prostate cancer with serial PSA, digital rectal examination (DRE), prostate magnetic resonance imaging and prostate biopsy. Since 2007, post-DRE urinary specimens have also been routinely obtained. Men with multiple PCA3 measures obtained over ⩾3 years of monitoring were included...
April 18, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28385586/-the-role-of-a-single-pca3-test-before-a-first-negative-prostate-biopsy-5-year-follow-up
#8
S Bernardeau, T Charles, G Fromont-Hankard, J Irani
PURPOSE: We report a 5-year follow-up of a cohort of patients who underwent a first prostate biopsy following a prostate cancer antigen 3 (PCA3) test. MATERIAL AND METHODS: We reviewed consecutive patients who had in 2008 a single urinary PCA3 test using the Gen-Probe(®) assay before a first prostate biopsy for a prostate-specific antigen (PSA) between 3 and 20ng/mL and/or a suspicious digital rectal examination. PCA3 performances were analyzed in 2008 and then in 2013 after taking into account the results of repeat biopsies...
April 3, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28380027/evaluation-of-a-short-rna-within-prostate-cancer-gene-3-in-the-predictive-role-for-future-cancer-using-non-malignant-prostate-biopsies
#9
Karl H Pang, Derek J Rosario, Susan L Morgan, James W F Catto
BACKGROUND: Prostate Cancer 3 (PCA3) is a long non-coding RNA (ncRNA) upregulated in prostate cancer (PCa). We recently identified a short ncRNA expressed from intron 1 of PCA3. Here we test the ability of this ncRNA to predict the presence of cancer in men with a biopsy without PCa. METHODS: We selected men whose initial biopsy did not identify PCa and selected matched cohorts whose subsequent biopsies revealed PCa or benign tissue. We extracted RNA from the initial biopsy and measured PCA3-shRNA2, PCA3 and PSA (qRT-PCR)...
2017: PloS One
https://www.readbyqxmd.com/read/28342633/pca3-as-a-second-line-biomarker-in-a-prospective-controlled-randomized-opportunistic-prostate-cancer-screening-programme
#10
J Rubio-Briones, J Casanova, F Martínez, J L Domínguez-Escrig, A Fernández-Serra, R Dumont, M Ramírez-Backhaus, A Gómez-Ferrer, A Collado, L Rubio, A Molina, M Vanaclocha, D Sala, J A Lopez-Guerrero
OBJECTIVES: PCA3 performance as a single second line biomarker is compared to the European Randomised Study of Screening for Prostate Cancer risk calculator model 3 (ERSPC RC-3) in an opportunistic screening in prostate cancer (PCa). MATERIAL AND METHODS: 5,199 men, aged 40-75y, underwent prostate-specific antigen (PSA) screening and digital rectal examination (DRE). Men with a normal DRE and PSA ≥3ng/ml had a PCA3 test done. All men with PCA3 ≥35 underwent an initial biopsy (IBx) -12 cores-...
March 22, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28293631/urinary-biomarker-panel-to-improve-accuracy-in-predicting-prostate-biopsy-result-in-chinese-men-with-psa-4-10%C3%A2-ng-ml
#11
Yongqiang Zhou, Yun Li, Xiangnan Li, Minjun Jiang
This study aims to evaluate the effectiveness and clinical performance of a panel of urinary biomarkers to diagnose prostate cancer (PCa) in Chinese men with PSA levels between 4 and 10 ng/mL. A total of 122 patients with PSA levels between 4 and 10 ng/mL who underwent consecutive prostate biopsy at three hospitals in China were recruited. First-catch urine samples were collected after an attentive prostate massage. Urinary mRNA levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR)...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28290096/the-value-and-evaluability-of-the-pca3-urine-assay-in-prostate-carcinoma-is-independent-of-the-tumor-localization
#12
Eva Neumann, Jörg Hennenlotter, Tilman Todenhöfer, Marcus Scharpf, Tim Neumann, David Schilling, Arnulf Stenzl, Jens Bedke
INTRODUCTION: The prostate cancer gene 3 (PCA3) test is based on the analysis of tumor cell mRNA in urine. As an exprimated urinary marker, its retrieval is subject to certain physical aspects like palpation pressure and detachment force during the squeezing of cells. Other potential factor of influence may be the distance the cells have to cover until they reach the urethra. Thus, it was investigated whether the localization of the tumors within the prostate with regard to the urethra and the seminal colliculus influences the PCA3 score...
March 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28241429/current-insights-into-long-non-coding-rnas-lncrnas-in-prostate-cancer
#13
REVIEW
Maria A Smolle, Thomas Bauernhofer, Karl Pummer, George A Calin, Martin Pichler
The importance of long non-coding RNAs (lncRNAs) in the pathogenesis of various malignancies has been uncovered over the last few years. Their dysregulation often contributes to or is a result of tumour progression. In prostate cancer, the most common malignancy in men, lncRNAs can promote castration resistance, cell proliferation, invasion, and metastatic spread. Expression patterns of lncRNAs often change during tumour progression; their expression levels may constantly rise (e.g., HOX transcript antisense RNA, HOTAIR), or steadily decrease (e...
February 22, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28212119/the-role-of-prostate-cancer-biomarkers-in-undiagnosed-men
#14
Hasan Dani, Stacy Loeb
PURPOSE OF REVIEW: This article intends to review biomarkers derived from blood, urine, and tissue that can aid in the diagnosis of prostate cancer (PCa). RECENT FINDINGS: PCa screening requires tools that complement prostate-specific antigen (PSA) with a higher specificity for clinically significant disease. Novel blood biomarkers, such as the Prostate Health Index (phi) and 4Kscore, utilize isoforms of PSA to more accurately predict high-grade PCa than traditional tools such as PSA and the percentage free-to-total PSA...
May 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28187449/low-pca3-expression-is-a-marker-of-poor-differentiation-in-localized-prostate-tumors-exploratory-analysis-from-12-076-patients
#15
Mohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, Maria Santiago-Jiménez, Nicholas Erho, Jennifer Jordan, Kasra Yousefi, Lucia L C Lam, Tyler Kolisnik, Jijumon Chelissery, Roland Seiler, Ashley E Ross, R Jeffrey Karnes, Edward M Schaeffer, Tamara T Lotan, Robert B Den, Stephen J Freedland, Elai Davicioni, Eric A Klein, Jack A Schalken
BACKGROUND: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p<0...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28115190/racial-variation-in-the-utility-of-urinary-biomarkers-pca3-and-t2erg-in-a-large-multicenter-study
#16
Padraic G O'Malley, Daniel P Nguyen, Bashir Al Hussein Al Awamlh, Guojiao Wu, Ian M Thompson, Martin Sanda, Mark Rubin, John T Wei, Richard Lee, Paul Christos, Christopher Barbieri, Douglas S Scherr
PURPOSE: To our knowledge it is unknown whether urinary biomarkers for prostate cancer have added utility to clinical risk calculators in different racial groups. We examined the utility of urinary biomarkers added to clinical risk calculators for predicting prostate cancer in African American and nonAfrican American men. MATERIALS AND METHODS: Demographics, PCPT (Prostate Cancer Prevention Trial) risk scores, data on the biomarkers data PCA3 (prostate cancer antigen 3) and T2ERG (transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog gene fusion), and biopsy pathology features were prospectively collected on 718 men as part of EDRN (Early Detection Research Network)...
January 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28061466/prostate-cancer-proteomics-current-trends-and-future-perspectives-for-biomarker-discovery
#17
REVIEW
Cristiana Pistol Tanase, Elena Codrici, Ionela Daniela Popescu, Simona Mihai, Ana-Maria Enciu, Laura Georgiana Necula, Adrian Preda, Gener Ismail, Radu Albulescu
The clinical and fundamental research in prostate cancer - the most common urological cancer in men - is currently entering the proteomic and genomic era. The focus has switched from one single marker (PSA) to panels of biomarkers (including proteins involved in ribosomal function and heat shock proteins). Novel genetic markers (such as Transmembrane protease serine 2 (TMPRSS2)-ERG fusion gene mRNA) or prostate cancer gene 3 (PCA3) had already entered the clinical practice, raising the question whether subsequent protein changes impact the evolution of the disease and the response to treatment...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/27995111/prostate-cancer-biomarkers-are-we-hitting-the-mark
#18
REVIEW
Shannon McGrath, Daniel Christidis, Marlon Perera, Sung Kyu Hong, Todd Manning, Ian Vela, Nathan Lawrentschuk
PURPOSE: Localised prostate cancer diagnosis and management is increasingly complex due to its heterogeneous progression and prognostic subgroups. Pitfalls in current screening and diagnosis have prompted the search for accurate and invasive molecular and genetic biomarkers for prostate cancer. Such tools may be able to distinguish clinically significant cancers from less aggressive variants to assist with prostate cancer risk stratification and guide decisions and healthcare algorithms...
December 2016: Prostate International
https://www.readbyqxmd.com/read/27925173/potential-of-long-non-coding-rnas-in-cancer-patients-from-biomarkers-to-therapeutic-targets
#19
REVIEW
Subash Chandra Gupta, Yashoda Nandan Tripathi
Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a biomarker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer and many other cancer types. Some lncRNAs have also been used as adjunct to improve the specificity and sensitivity of existing biomarkers. The molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE and quantitative real-time PCR have been used for examining the lncRNAs' potential...
May 1, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27922627/blood-based-and-urinary-prostate-cancer-biomarkers-a-review-and-comparison-of-novel-biomarkers-for-detection-and-treatment-decisions
#20
REVIEW
R J Hendriks, I M van Oort, J A Schalken
BACKGROUND: The diagnosis of prostate cancer (PCa) is currently based on serum PSA testing and/or abnormal digital rectal examination and histopathologic evaluation of prostate biopsies. The main drawback of PSA testing is the lack of specificity for PCa. To improve early detection of PCa more specific biomarkers are needed. In the past few years, many new promising biomarkers have been identified; however, to date, only a few have reached clinical practice. METHODS: In this review, we discuss new blood-based and urinary biomarker models that are promising for usage in PCa detection, follow-up and treatment decision-making...
December 6, 2016: Prostate Cancer and Prostatic Diseases
keyword
keyword
17649
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"